PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Biochim Biophys Acta. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
PMCID: PMC2743791
NIHMSID: NIHMS119635

Forkhead box transcription factor O1 inhibits cholesterol 7α-hydroxylase in human hepatocytes and in high fat diet-fed mice

Abstract

The conversion of cholesterol to bile acids is the major pathway for cholesterol catabolism. Bile acids are metabolic regulators of triglycerides and glucose metabolism in the liver. This study investigated the roles of FoxO1 in the regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression in primary human hepatocytes. Adenovirusmediated expression of a phosphorylation defective and constitutively active form of FoxO1 (FoxO1-ADA) inhibited CYP7A1 mRNA expression and bile acid synthesis, while siRNA knockdown of FoxO1 resulted in a ~ 6-fold induction of CYP7A1 mRNA in human hepatocytes. Insulin caused rapid exclusion of FoxO1 from the nucleus and resulted in induction of CYP7A1 mRNA expression, which was blocked by FoxO1-ADA. In high fat diet-fed mice, CYP7A1 mRNA expression was repressed and inversely correlated to increased hepatic FoxO1 mRNA expression and FoxO1 nuclear retention. In conclusion, our current study provides direct evidence that FoxO1 is strong repressor of CYP7A1 gene expression and bile acid synthesis. Impaired regulation of FoxO1 may cause down-regulation of CYP7A1 gene expression and contribute to dyslipidemia in insulin resistance.

Keywords: bile acid synthesis, insulin, gene expression, nuclear receptor, metabolic diseases

1. Introduction

The conversion of cholesterol to bile acids is the predominant pathway for cholesterol catabolism. Bile acids facilitate intestinal fat and vitamin absorption and hepatic disposal of toxic metabolites and xenobiotics [1]. Approximately 95% of bile acids are reabsorbed in the intestine, transported back to the liver to inhibit bile acid synthesis. This circulation of bile acids between liver and intestine is referred to as the enterohepatic circulation of bile acids. Bile acids are endogenous ligands of the nuclear receptor farnesoid X receptor (FXR) [2]. FXR plays a central role in med mediating bile acid inhibition of cholesterol 7α-hydroxylase (CYP7A1), the first and rate-limiting enzyme in bile acid biosynthesis [1]. Two FXR-mediated pathways for bile acid inhibition of CYP7A1 gene transcription have been proposed. In the liver, FXR induces a negative nuclear receptor small heterodimer partner (SHP) that interacts with liver related homologue-1 (LRH-1) to repress CYP7A1 gene transcription [3]. In the intestine, FXR induces fibroblast growth factor 15 (FGF15), which activates hepatocyte FGF receptor 4 (FGFR4) signaling to repress CYP7A1 gene transcription [4]. CYP7A1 is also repressed during hepatic injury and inflammation by pro-inflammatory cytokines as an adaptive response to protect the liver from bile acid cytotoxicity [5, 6]. Bile acids and FXR agonists reduce serum triglyceride levels by inhibition of lipogenesis and stimulation of triglyceride clearance, and improve hyperglycemia and insulin sensitivity in diabetic animal models [7-11].

FoxO1 belongs to the family of Forkhead box transcription factors. FoxO1 induces the gluconeogenic genes and contributes to hyperglycemia during hepatic insulin resistance [12, 13]. FoxO1 is a direct target of insulin signaling. Phosphorylation of FoxO1 by PKB/AKT promotes FoxO1 nuclear exclusion and proteosome degradation in the cytosol [14-16]. This insulin-controlled sub-cellular localization of FoxO1 provides the molecular basis of insulin action on controlling hepatic glucose and lipid metabolism [17]. FoxO1 expression and nuclear localization are increased in non-alcoholic steatohepatitis and in mouse models of diabetes and obesity [18, 19]. Increased hepatic expression of FoxO1 is associated with elevated hepatic glucose production and fatty accumulation in mice [20, 21]. Inhibition of hepatic FoxO1 by genetic ablation or an antisense oligonucleotide decreases hepatic glucose production and steatosis, and improves insulin sensitivity in diabetic mice [22, 23].

A previous study from this laboratory shows that physiological concentrations of insulin stimulate CYP7A1 mRNA expression in primary human hepatocytes and FoxO1 inhibits CYP7A1 promoter/reporter activity [24]. In this study, we further investigated the role of FoxO1 in mediating insulin regulation of the CYP7A1 gene in primary human hepatocytes and in a mouse model of diet-induced insulin resistance. Our study suggests that FoxO1 is a key factor involved in the regulation of CYP7A1 gene transcription. Dysregulation of FoxO1 activity in insulin resistance and fatty liver diseases may lead to down-regulation of CYP7A1 gene expression and bile acid synthesis, which may contribute to impaired hepatic lipid homeostasis.

2. Materials and methods

2.1. Cell Culture

The human hepatoblastoma cell line, HepG2, was purchased from American Type Culture Collection (Manassas, VA). The cells were cultured in Dulbecco's modified Eagle medium and F-12 (Sigma, St. Louis, MO) supplemented with 100U/ml penicillin G/streptomycin sulfate (Mediatech, Herndon, VA) and 10% (v/v) heat-inactivated fetal bovine serum (Irvine Scientific, Santa Ana, CA). Primary human hepatocytes were isolated from human donors and were obtained through the Liver Tissue Procurement and Distribution System of the National Institutes of Health (S. Strom, University of Pittsburgh, Pittsburgh, PA). Cells were maintained in Hepatocyte Maintenance Medium (HMM) supplemented with 10-7 M of insulin and dexamethasone (Lonza, Walkersville Inc, MD). Cells were cultured in insulin-free media for 24 hr before performing all experiments.

2.2. RNA Isolation and Quantitative Real-time PCR

RNA isolation, reverse transcription reactions and real time PCR were performed as described previously [24]. All primers/probe used were TaqMan Gene Expression Assays purchased from Applied Biosystems (Foster City, CA). Amplification of Ubiquitin C (UBC) was used as an internal control. Relative mRNA expression was quantified using the comparative CT (Ct) method and expressed as 2 -ΔΔCt.

2.3. Chromatin Immunoprecipitation (ChIP) Assay

ChIP assays were performed as described previously [6]. Antibodies against HAtag, HNF4αand PGC-1α(Santa Cruz Biotechnology, Santa Cruz, CA) were used to immuno-precipitate chromatin. TaqMan primers/probe were designed to detect the CYP7A1 promoter region containing a previously identified bile acid response element that binds HNF4α(-180 to -111) and the human PEPCK gene proximal promoter containing the HFN4 and FoxO1 binding sites (-490 to -406). Quantitative real-time PCR was used to quantify the ChIP assay. The non-specific background detected in negative controls immunoprecipitated with non-immune IgG was subtracted from the precipitated CYP7A1 chromatin. The relative binding strength was expressed in arbitrary units with control set as “1”.

2.4. Recombinant Adenovirus

Adeno-EGFP was obtained from Dr. Li Wang (University of Utah, Salt Lake City, UT). Adeno-siFoxO1, Adeno-FoxO1-ADA expressing an N-terminal HA-tagged constitutively active FoxO1 and Adeno-FoxO1-Δ256 [17] expressing an N-terminal HAtagged truncated form of FoxO1, which lacks the C-terminal trans-activation domain and binds DNA as a dominant negative form were provided by Dr. D. Accili (Columbia University, NY). Recombinant adenoviruses were amplified in HEK293A cells and purified with Adeno-X Virus mini purification kit (BD Biosciences, San Jose, CA). Virus titer was determined by Ad-easy viral titer kit (Stratagene).

2.5. GST Pull-down Assay

GST or GST-full length human HNF4αfusion protein was expressed in E. coli BL21 cells. Bacterial cell lysate containing either GST or GST-HNF4 fusion protein was then incubated with glutathione-conjugated argarose beads for 2 hr at 4 degree. Beads were then washed three times in 1 X PBS and resuspended in 1 X PBS as 50% slurry. HepG2 cells were infected with adenovirus expressing HA-tagged FoxO1-ADA or HA-tagged FoxO1-Δ256 for 48 hr. Cells were collected by centrifugation and resuspended in 1X-GST binding buffer (1X PBS, 0.1% NP40, 0.5mM DTT, 10% Glycerol) and lysed by sonication. HepG2 cell lysates and fusion protein bound glutathione-argarose beads were then incubated at 4 degree for 2 hr. Beads were washed three times in GST wash buffer (1X PBS, 0.1% NP40, 0.5mM DTT, 100 mM KCl), and bound protein was eluted in 1% SDS lysis buffer at 95 degree and used for western blot detection of FoxO1-ADA or FoxO1-Δ256 with an anti-HA antibody (Santa Cruz Biotechnology, CA). Ten % of whole cell lysates were used as “Input” controls.

2.6. Immunofluorescence Staining

Cells were fixed with 4% formaldehyde and permeablized with 0.1% TritonX100. Anti-FoxO1 (Cell Signaling Technology, Danvers, MA) or anti-HA (Santa Cruz Biotechnology, CA) antibodies were used for detecting endogenous FoxO1 or exogenously expressed FoxO1-ADA, respectively. Alexa Fluor 488 conjugated secondary antibody (Molecular Probes, Carlsbad, CA) was used for detection under a confocal microscope. Non-immune IgG was used as background control.

2.7. Quantification of Total Bile Acids

Total bile acids from whole cell lysates and culture media were extracted with the Sep-Pak C18 cartridge (Walters Corp., Milford, MA) and quantified with total bile acid colorimetric assay kit (Bio-Quant, San Diego, CA) following the manufacturer's instruction.

2.8. Animal Study

Age-matched C57BL/6 male mice were fed either a standard chow diet or a high fat Western diet containing 42% fat calories (saturated fat from anhydrous milk fat) + 0.2% cholesterol (TD88137, Harlan Teklad) for a period of 20 weeks. Body weight was measured at 18 weeks of feeding. Mice were housed in a room under 12 h light and dark cycle (7 am on, 7 pm off). All mice were sacrificed around 10:00 am after over night fasting.

2.9. Analysis of plasma and hepatic lipids

Total liver cholesterol, triglyceride and free fatty acids were analyzed using lipid analysis kits (triglycerides and cholesterol, Thermo Electron Co., non-esterified fatty acids, Wako Chemicals Inc., Richmond, VA) following the manufacturer's instructions after chloroform/methanol (2:1 v/v) extraction [25]. Plasma insulin was measured using an ELISA kit (Crystal Chem, Chicago, IL). Plasma non-esterified fatty acids, triglycerides, cholesterol, glucose, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured by the Comparative Pathology Laboratory at Baylor College of Medicine.

2.10. Statistical Analysis

Results from cell-based studies were expressed as mean ± S.D. Results from animal studies are expressed as mean ± SEM. All statistical analyses were performed with student's t-test. A p value of <0.05 was considered as statistically significant difference between two groups.

3. Results

3.1. Adenovirus-mediated gene transfer of FoxO1 represses CYP7A1 and bile acid synthesis in human primary hepatocytes

In our previous study, we showed that physiological concentrations of insulin rapidly induced CYP7A1 mRNA expression in primary human hepatocytes and FoxO1 repressed human CYP7A1 reporter activity [24]. To directly test the effect of FoxO1 on CYP7A1 mRNA expression, we infected primary human hepatocytes with recombinant adenovirus expressing a phosphorylation defective and constitutively active form of FoxO1 (ADA) (Fig 1A, inset). Expression of FoxO1-ADA resulted in 60% inhibition of CYP7A1 mRNA expression, but had no effect on the mRNA expression of CYP27A1 mRNA expression (negative control). FoxO1-ADA significantly inhibited total bile acid synthesis by ~ 50% in primary human hepatocytes (Fig. 1B).

Figure 1
FoxO1-ADA inhibited CYP7A1 mRNA expression in primary human hepatocytes

To test the hypothesis that FoxO1 directly interacts with HNF4αand results in inhibiting CYP7A1 gene transcription, we performed GST pull down assays. As shown in Fig 2A, the GST-HNF4αfusion protein interacted with both the constitutively active FoxO1-ADA, and the dominant negative FoxO1-Δ256 suggesting that HNF4α may interact with FoxO1 through the N-terminal region that contains the DNA binding domain. Adenovirus-mediated transduction of FoxO1-Δ256 in human hepatocytes also resulted in ~ 70% repression of CYP7A1 mRNA expression (data not shown), suggesting that FoxO1 regulation of CYP7A1 is independent of its transactivating activity. Furthermore, ChIP assays showed that adenovirus-mediated transduction of FoxO1-ADA in primary human hepatocytes increased the association of FoxO1-ADA to the CYP7A1 chromatin (Fig 2B, left panel). FoxO1-ADA did not affect HNF4αbinding (Fig 2B, middle panel), but decreased its recruitment of PGC-1α to CYP7A1 chromatin (Fig. 2B, right panel). We did ChIP assay of the human phosphoenolpyruvate carboxykinase (PEPCK) gene promoter as a control. FoxO1 and HNFαare known to bind PEPCK promoter and stimulate PEPCK gene transcription. As shown in Fig 2C, FoxO1-ADA did not affect the HNF4αand PGC-1αbinding to the PEPCK gene promoter. These results suggest that FoxO1 acts as a co-repressor of HNF4α, which blocks HNF4αinteraction with PGC-1α and results in inhibition of CYP7A1 gene transcription. This mechanism seems to be specific for regulation of CYP7A1, but not PEPCK.

Figure 2
FoxO1 interacted with HNF4αand repressed CYP7A1 mRNA expression

3.2. Knocking down of endogenous FoxO1 by RNA interference induces CYP7A1 mRNA expression in primary human hepatocytes

To further test the role of FoxO1 in regulating CYP7A1 gene expression, we used adenovirus-mediated transfer of FoxO1 siRNA (Ad-siFoxO1) to knock down endogenous FoxO1 expression in primary human hepatocytes. Fig. 3A shows that Ad-siFoxO1 reduced FoxO1 mRNA and protein levels by ~ 50% in primary human hepatocytes. Interestingly, such a decrease in endogenous FoxO1 expression resulted in a 6-fold increase in CYP7A1 mRNA expression (Fig. 3B). Immunostaining assays showed that FoxO1 was predominantly localized in hepatocyte nuclei (Supplemental Fig. 1). This loss-of-function study demonstrated that FoxO1 is a strong repressor of CYP7A1 gene expression.

Figure 3
Knocking down endogenous FoxO1 induced CYP7A1 mRNA expression in primary human hepatocytes

3.3. Retention of FoxO1 in the nucleus prevented insulin induction of CYP7A1 mRNA expression

We next evaluated the role of FoxO1 in mediating insulin regulation of CYP7A1 mRNA expression in human primary hepatocytes by expressing a phosphorylation defective and constitutively active FoxO1 in human hepatocytes. Fluorescence imaging (Supplemental Fig. 1) shows that insulin treatment for 2 hr resulted in nuclear exclusion of endogenous FoxO1 in non-infected human hepatocytes (upper panel), but had no effect on exogenously expressed FoxO1-ADA that was exclusively localized in the nuclei (lower panel). To test how this FoxO1-ADA may affect insulin induction of CYP7A1 mRNA expression, hepatocytes were infected with adenovirus expressing either EGFP (negative control) or FoxO1-ADA and cultured for an additional 24 hr in insulin-free media. Cells were then treated with vehicle or insulin (10 nM) for 2 hr. Fig. 4 shows that insulin (10 nM) treatment caused a 5-fold induction of CYP7A1 mRNA in Ad-EGFP infected cells (negative control) as expected. Adenovirus-mediated transduction of FoxO1-ADA blocked insulin induction of CYP7A1 mRNA expression in primary human hepatocytes (Fig 4). These results provided the evidence that FoxO1 retained in the nuclei directly inhibited CYP7A1 gene transcription in human hepatocytes.

Figure 4
Constitutively active FoxO1 blocked insulin induction of CYP7A1

3.4. The CYP7A1 gene is down regulated in mice of high fat diet-induced insulin resistance

In order to gain further insights into the FoxO1 regulation of CYP7A1 in vivo, we fed mice a high fat Western diet for 20 weeks to study CYP7A1 expression. High-fat diet-fed mice developed fatty livers with severe hepatic accumulation of triglycerides, free fatty acids and cholesterol. A trend toward increased plasma AST and ALT levels was also noted in Western diet-fed mice, although they did not reach statistical significance. Consistent with hepatic fatty accumulation, high fat diet-fed mice showed a 3-fold increase in fasting plasma insulin levels over that of control mice, indicating impaired insulin sensitivity (Supplemental Table 1). Western diet-fed mice also showed elevated plasma cholesterol levels, but normal plasma triglycerides and free fatty acid levels (Table 1). Gene expression analysis by real-time PCR showed that high fat diet feeding caused ~ 60% decrease of CYP7A1 mRNA expression in mouse livers (Fig. 5A). Although the hepatic mRNA expression of FoxO1 was not significantly increased (Fig. 5A), high fat diet feeding resulted in a significant increase in nuclear content of FoxO1 protein (Fig. 5B). These results suggest that in hepatic steatosis and insulin resistant conditions, both oxidative stress [26] and impaired insulin signaling [21] may cause nuclear accumulation of FoxO1, which inhibits CYP7A1 expression and bile acid synthesis

Figure 5
Decreased expression of cyp7a1 mRNA in livers of western diet-fed mice

4. Discussion

Numerous studies in the past have established that dysregulation of FoxO1 contributes to both impaired hepatic glucose production and lipid metabolism. Using cellbased reporter assays, we showed previously that co-transfection of FoxO1 into HepG2 cells repressed a human CYP7A1 promoter/luciferase reporter activity, indicating that FoxO1 may regulate hepatic bile acid synthesis [24]. However, direct evidence for FoxO1 regulation of CYP7A1 expression and bile acid synthesis in human hepatocyte is still lacking. In this study, we employed adenovirus-mediated transfer of constitutively activate FoxO1 as a gain-of-function and siRNA to FoxO1 as a loss-of-function to study the role of FoxO1 on CYP7A1 gene expression in primary human hepatocytes. Furthermore, we examined the role of FoxO1 in regulation of CYP7A1 gene expression in a mouse model of high fat diet-induced insulin resistance. In this study, we demonstrated that the constitutively activate FoxO1 inhibits CYP7A1 expression and bile acid synthesis whereas knockdown of FoxO1 by RNA interference strongly stimulates CYP7A1 expression in human hepatocytes. The fact that expression of a phosphorylation defective FoxO1 completely abolished the insulin effect on the CYP7A1 gene provides direct evidence that FoxO1 is the down stream mediator of insulin action and a strong repressor of human CYP7A1 gene expression. Our data suggest that FoxO1 directly interacts with HNF4αto reduce PGC-1αoccupancy in CYP7A1 chromatin and results in inhibiting CYP7A1 gene transcription. FoxO1 is subject to a complex regulation by cellular signaling pathways and post-translational modifications to affect FoxO1 cellular localization and activity [26-28]. It would be interesting to study how FoxO1 may regulate bile acid synthesis in response to different cellular stimuli.

Regulation of CYP7A1 gene expression in insulin resistance and hepatic dyslipidemia is currently unclear. This study also attempted to investigate the role of FoxO1 in CYP7A1 gene regulation in such disease conditions using long-term Western diet-fed mice as an in vivo model. This high saturated fat and high cholesterol-containing diet mimics the human “Western” diet and has been widely used in rodents for the studies of metabolic syndromes [29-32]. Consistent with these studies, we found that high fat diet feeding resulted in fatty livers and insulin resistance in these mice as reflected by excessive hepatic lipid accumulation and hyperinsulinemia (Table 1). We found that cyp7a1 mRNA expression levels were markedly decreased in livers of high fat diet-fed mice when compared to chow-fed mice. This correlates with a significant increase in FoxO1 nuclear retention in hepatocytes, suggesting that increased FoxO1 nuclear retention may contribute to the down-regulation of the Cyp7a1 gene as in primary human hepatocytes. These findings are also consistent with previous reports that feeding mice a diet containing high cholesterol and high saturated fat, but not polyunsaturated fat, inhibited cyp7a1 gene expression, activity and bile acid pool [33, 34]. Impaired insulin signaling may contribute to increased FoxO1 nuclear retention. How different dietary fat may regulate FoxO1 is currently not clear. Saturated fat accumulation in the liver may lead to oxidative stress and activation of JNK pathway to cause FoxO1 nuclear retention [26]. It should be noted that hepatic steatosis is usually associated with elevated hepatic production of cytokines [32]. We also found that hepatic expression of inflammatory cytokines TNFα and IL-1β were all significantly increased (data not shown),it is likely that cytokine activation may also play a significant role in inhibition of CYP7A1 gene expression in hepatic fatty accumulation and inflammation [35].

In conclusion, this study provides direct evidence that FoxO1 is a repressor of CYP7A1 gene transcription and may be implicated in regulation of hepatic bile acid synthesis in diabetes and fatty liver diseases. Down-regulation of CYP7A1 in insulin resistance and fatty liver disease may lead to disrupted bile acid homeostasis, which may contribute to dyslipidemia by affecting cholesterol, triglyceride and glucose metabolism.

Supplementary Material

5. Acknowledgements

This study was supported by NIH grants DK58379 and DK44442. T. Li is a recipient of the American Heart Association Great Rivers Affiliate Postdoc Fellowship

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Reference

[1] Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol. 2004;40:539–551. [PubMed]
[2] Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365. [PubMed]
[3] Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517–526. [PubMed]
[4] Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225. [PubMed]
[5] Miyake JH, Wang SL, Davis RA. Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7alphahydroxylase. J Biol Chem. 2000;275:21805–21808. [PubMed]
[6] Li T, Chiang JY. A novel role of transforming growth factor beta1 in transcriptional repression of human cholesterol 7alpha-hydroxylase gene. Gastroenterology. 2007;133:1660–1669. [PubMed]
[7] Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113:1408–1418. [PMC free article] [PubMed]
[8] Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–11049. [PubMed]
[9] Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006–1011. [PubMed]
[10] Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F, Staels B. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem. 2005;280:29971–29979. [PubMed]
[11] Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116:1102–1109. [PubMed]
[12] Schmoll D, Walker KS, Alessi DR, Grempler R, Burchell A, Guo S, Walther R, Unterman TG. Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity. J Biol Chem. 2000;275:36324–36333. [PubMed]
[13] Hall RK, Yamasaki T, Kucera T, Waltner-Law M, O'Brien R, Granner DK. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factorbinding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. J Biol Chem. 2000;275:30169–30175. [PubMed]
[14] Biggs WH, 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A. 1999;96:7421–7426. [PubMed]
[15] Guo S, Rena G, Cichy S, He X, Cohen P, Unterman T. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem. 1999;274:17184–17192. [PubMed]
[16] Nakae J, Park BC, Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem. 1999;274:15982–15985. [PubMed]
[17] Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest. 2001;108:1359–1367. [PMC free article] [PubMed]
[18] Valenti L, Rametta R, Dongiovanni P, Maggioni M, Fracanzani AL, Zappa M, Lattuada E, Roviaro G, Fargion S. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes. 2008;57:1355–1362. [PubMed]
[19] Qu S, Altomonte J, Perdomo G, He J, Fan Y, Kamagate A, Meseck M, Dong HH. Aberrant FoxO1 Function Is Associated with Impaired Hepatic Metabolism. Endocrinology. 2006 [PMC free article] [PubMed]
[20] Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D, Spiegelman BM. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423:550–555. [PubMed]
[21] Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116:2464–2472. [PubMed]
[22] Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, McKay R, Monia B, Shutter JR, Lindberg RA, Shulman GI, Veniant MM. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes. 2006;55:2042–2050. [PubMed]
[23] Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 2007;6:208–216. [PubMed]
[24] Li T, Kong X, Owsley E, Ellis E, Strom S, Chiang JY. Insulin regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element-binding protein 1c. J Biol Chem. 2006;281:28745–28754. [PMC free article] [PubMed]
[25] Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497–509. [PubMed]
[26] Kawamori D, Kaneto H, Nakatani Y, Matsuoka TA, Matsuhisa M, Hori M, Yamasaki Y. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem. 2006;281:1091–1098. [PubMed]
[27] Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, Puigserver P, Hart GW. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem. 2008;283:16283–16292. [PMC free article] [PubMed]
[28] Yamagata K, Daitoku H, Takahashi Y, Namiki K, Hisatake K, Kako K, Mukai H, Kasuya Y, Fukamizu A. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell. 2008;32:221–231. [PubMed]
[29] Prada PO, Zecchin HG, Gasparetti AL, Torsoni MA, Ueno M, Hirata AE, Corezola do Amaral ME, Hoer NF, Boschero AC, Saad MJ. Western diet modulates insulin signaling, c-Jun N-terminal kinase activity, and insulin receptor substrate-1ser307 phosphorylation in a tissue-specific fashion. Endocrinology. 2005;146:1576–1587. [PubMed]
[30] Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology. 2006;44:1191–1205. [PubMed]
[31] Hartvigsen K, Binder CJ, Hansen LF, Rafia A, Juliano J, Horkko S, Steinberg D, Palinski W, Witztum JL, Li AC. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007;27:878–885. [PubMed]
[32] Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology. 2007;46:1392–1403. [PubMed]
[33] Cheema SK, Cikaluk D, Agellon LB. Dietary fats modulate the regulatory potential of dietary cholesterol on cholesterol 7 alpha-hydroxylase gene expression. J Lipid Res. 1997;38:315–323. [PubMed]
[34] Li Y, Hou MJ, Ma J, Tang ZH, Zhu HL, Ling WH. Dietary fatty acids regulate cholesterol induction of liver CYP7alpha1 expression and bile acid production. Lipids. 2005;40:455–462. [PubMed]
[35] Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology. 2006;43:1202–1210. [PMC free article] [PubMed]